Coverage policy updates

Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.

Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.

Recorded changes

83,427 on record

Recorded policy changes, newest first
Recorded	Payer	Policy	Change
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE AND SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN PROSTATE CANCER (BRCA1/2, HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS), NTRK GENE FUSIONPayerPolicy · BCBSM-2183047	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING - CHROMOSOMAL MICROARRAY (CMA) ANALYSIS AND NEXT-GENERATION SEQUENCING PANELS, FOR THE EVALUATION OF CHILDREN WITH DEVELOPMENTAL DELAY/INTELLECTUAL DISABILITY, AUTISM SPECTRUM DISORDER, AND/OR CONGENITAL ANOMALIESPayerPolicy · BCBSM-2003173	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	DRUG COATED BALLOON FOR BENIGN PROSTATIC HYPERPLASIA LOWER URINARY TRACT SYMPTOMS & URETHRAL STRICTURES (I.E., OPTILUME DRUG COATED BALLOON) (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209362-A6764802A3	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SCREENING FOR LUNG CANCER AND PULMONARY NODULE EVALUATION USING LOW DOSE COMPUTED TOMOGRAPHY (CT) SCANNING AND COMPUTER AIDED DETECTION (CAD) (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209379-FA6621C8D2	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE GENETIC TESTING FOR GENE VARIANTS ASSOCIATED WITH BREAST CANCER IN INDIVIDUALS AT MODERATE AND HIGH BREAST CANCER RISK (E.G., CHEK2, ATM, BARD1, ETC.) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198905	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN METASTATIC COLORECTAL CANCER (KRAS, NRAS,BRAF, NTRK, RET AND HER2) (EFFECTIVE 01/01/2026)PayerPolicy · BCBSM-2203597	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (E.G., CEFALY, ETNS, AXON) AND TRANSCUTANEOUS AFFERENT PATTERNED STIMULATION (E.G., CALA ONE, CALA TRIO CALA KLQ)- MEDICARE ADVANTAGEPayerPolicy · BCBSM-2201631	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	90759 - HEPATITIS B VACCINE (HEPB), 3-ANTIGEN (S, PRE-S1, PRE-S2) 10 MCG DOSAGE, 3 DOSE SCHEDULE, FOR INTRAMUSCULAR USEPayerPolicy · BCBSM-2161422	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE AND SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN PROSTATE CANCER (BRCA1/2, HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2197830	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	MEASUREMENT OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) AND SECRETORY TYPE II PHOSPHOLIPASE A2 (SPLA2-IIA) IN THE ASSESSMENT OF CARDIOVASCULAR RISK - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2197060	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT AND IMMUNOTHERAPY IN METASTATIC COLORECTAL CANCER (KRAS, NRAS, BRAF, MMR/MSI, HER2, AND TMB)PayerPolicy · BCBSM-2022187	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (E.G., CEFALY, ETNS, AXON) AND TRANSCUTANEOUS AFFERENT PATTERNED STIMULATION (E.G., CALA ONE, CALA TRIO, CALA KLQ,)PayerPolicy · BCBSM-2199089	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	MULTIMARKER SERUM-BASED TESTING RELATED TO OVARIAN CANCER (E.G., OVA1, OVERA, OVAWATCH, GLYCOKNOW OVARIAN AND ROMA TESTING) (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209378-392273413B	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE GENETIC TESTING FOR GENE VARIANTS ASSOCIATED WITH BREAST CANCER IN INDIVIDUALS AT MODERATE AND HIGH BREAST CANCER RISK (E.G., CHEK2, ATM, BARD1, ETC.)PayerPolicy · BCBSM-2117516	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE AND SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN OVARIAN CANCER (BRCA1, BRCA2, HOMOLOGOUS RECOMBINATION DEFICIENCY) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2197829	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING NONINVASIVE PRENATAL SCREENING FOR FETAL ANEUPLOIDIES, MICRODELETIONS, SINGLE-GENE DISORDERS, AND TWIN ZYGOSITY USING CELL-FREE FETAL DNAPayerPolicy · BCBSM-2058206	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	BMT - HEMATOPOIETIC CELL TRANSPLANTATION FOR PLASMA CELL DYSCRASIAS, INCLUDING MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, PLASMACYTOMA, AND POEMS SYNDROME - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2195789	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	INTENSITY-MODULATED RADIATION THERAPY (IMRT) AND IMAGE GUIDED RADIATION THERAPY (IGRT): CANCER OF THE HEAD AND NECK OR THYROID (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209370-FF9694DE6D	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	INTENSITY MODULATED RADIATION THERAPY (IMRT) AND IMAGE GUIDED RADIATION THERAPY (IGRT): CENTRAL NERVOUS SYSTEM TUMORS (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209371-61F868F3A7	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	ADJUNCTIVE TECHNIQUES FOR SCREENING, SURVEILLANCE, AND RISK CLASSIFICATION OF BARRETT ESOPHAGUS AND ESOPHAGEAL DYSPLASIA (E.G., WATS3D, TISSUECYPHER, ESOCHECK, ESOGUARD, ESOPREDICT) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2210409	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING FOR FMR1 VARIANTS (INCLUDING FRAGILE X SYNDROME) AND FMR2 VARIANTS (INCLUDING FRAGILE XE SYNDROME) (EFFECTIVE 09/01/2026)PayerPolicy · BCBSM-2210508-A97EB2D942	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING-ASSAYS OF GENETIC EXPRESSION IN TUMOR TISSUE AS A TECHNIQUE TO HELP GUIDE DECISION-MAKING IN PATIENTS WITH BREAST CANCER - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198879	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	MEDICAL POLCIY - GERMLINE AND SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN OVARIAN CANCER (BRCA1, BRCA2, HOMOLOGOUS RECOMBINATION DEFICIENCY,NTRK)PayerPolicy · BCBSM-2183704	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GERMLINE GENETIC TESTING FOR BRCA1, BRCA2, AND PALB2 FOR HEREDITARY BREAST/OVARIAN CANCER SYNDROME AND OTHER HIGH-RISK CANCERS - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198024	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	BMT - HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) (EFFECTIVE 01/01/2026)PayerPolicy · BCBSM-2203607	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SPINAL SURGERY-IMAGE-GUIDED MINIMALLY INVASIVE LUMBAR DECOMPRESSION (IG-MLD, MELD, PERCUTANEOUS IG-MLD OR PILD) FOR SPINAL STENOSISPayerPolicy · BCBSM-2020291	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) AND TREATMENT RESPONSE LABORATORY TESTING (E.G., VECTRA¿ DA, PRISMRA) FOR RHEUMATOID ARTHRITIS - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2197627	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SCREENING FOR LUNG CANCER AND PULMONARY NODULE EVALUATION USING LOW DOSE COMPUTED TOMOGRAPHY (CT) SCANNING AND COMPUTER AIDED DETECTION (CAD)PayerPolicy · BCBSM-77004	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	ACCELERATED BREAST IRRADIATION AND WHOLE BREAST IRRADIATION WITH BOOST AFTER BREAST-CONSERVING SURGERY FOR EARLY-STAGE BREAST CANCER - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2190897	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	MEASUREMENT OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) AND SECRETORY TYPE II PHOSPHOLIPASE A2 (SPLA2-IIA) IN THE ASSESSMENT OF CARDIOVASCULAR RISKPayerPolicy · BCBSM-105873	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	INTENSITY-MODULATED RADIATION THERAPY (IMRT) AND IMAGE GUIDED RADIATION THERAPY (IGRT): ABDOMEN, PELVIS, AND CHEST (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209368-ED8EF1AD56	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	DRUG COATED BALLOON FOR BENIGN PROSTATIC HYPERPLASIA LOWER URINARY TRACT SYMPTOMS & URETHRAL STRICTURES (I.E., OPTILUME DRUG COATED BALLOON)PayerPolicy · BCBSM-2209859	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	STEERABLE URETEROSCOPIC RENAL EVACUATION (SURE PROCEDURE) WITH VACUUM-ASSISTED STONE REMOVAL SYSTEMS FOR KIDNEY STONE MANAGEMENT- MEDICARE ADVANTAGEPayerPolicy · BCBSM-2205431	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	PERCUTANEOUS ELECTRICAL NERVE STIMULATION (PENS) AND PERCUTANEOUS NEUROMODULATION THERAPY (PNT) AND RESTORATIVE NEUROSTIMULATION THERAPY (E.G., REACTIV8) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2197264	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	CONTRAST-ENHANCED COMPUTED TOMOGRAPHY ANGIOGRAPHY (CTA, CCTA, MDCT, MSCT) OF THE HEART AND/OR CORONARY ARTERIES (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209363-F786AACAB5	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING - MOLECULAR TESTING FOR THE DIAGNOSIS AND MANAGEMENT OF PANCREATIC CYSTS, AND SOLID PANCREATICOBILIARY LESIONS (E.G., PATHFINDERTG, PANCRAGEN) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198828	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	INTENSITY MODULATED RADIATION THERAPY (IMRT) AND IMAGE GUIDED RADIATION THERAPY (IGRT) OF THE BREAST AND LUNG (EFFECTIVE 07/01/2026)PayerPolicy · BCBSM-2209369-F16B710492	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	ADJUNCTIVE TECHNIQUES FOR SCREENING, SURVEILLANCE, AND RISK CLASSIFICATION OF BARRETT ESOPHAGUS AND ESOPHAGEAL DYSPLASIA (E.G., WATS3D, TISSUECYPHER, ESOCHECK, ESOGUARD, ESOPREDICT)PayerPolicy · BCBSM-2208108	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	TRANSESOPHAGEAL ENDOSCOPIC THERAPIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) (TRANSORAL INCISIONLESS FUNDOPLICATION - TIF [ESOPHYX, MUSE, GERDX) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2193022	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	ANALYSIS OF HUMAN FIT-DNA (I.E.,COLOGUARD) AND FIT-RNA (I.E., COLOSENSE) IN STOOL SAMPLES AS A TECHNIQUE FOR COLORECTAL CANCER SCREENINGPayerPolicy · BCBSM-76822	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN METASTATIC COLORECTAL CANCER (KRAS, NRAS, BRAF NTRK, AND HER2)PayerPolicy · BCBSM-2192027	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	CIRCULATING TUMOR DNA AND CIRCULATING TUMOR CELLS FOR SELECTING TARGETED THERAPY FOR ADVANCED SOLID CANCERS (LIQUID BIOPSY) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198907	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	BMT - HEMATOPOIETIC CELL TRANSPLANTATION FOR PLASMA CELL DYSCRASIAS, INCLUDING MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, PLASMACYTOMA, AND POEMS SYNDROMEPayerPolicy · BCBSM-82433	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GT - SOMATIC BIOMARKER TESTING FOR IMMUNE CHECKPOINT INHIBITOR THERAPY (BRAF, MSI/MMR, PD-L1, TMB) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198902	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	BONE TURNOVER MARKERS FOR DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS AND DISEASES ASSOCIATED WITH HIGH BONE TURNOVER (EFFECTIVE 09/01/2026)PayerPolicy · BCBSM-2210517-4738A948E6	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	ORTHOPEDIC APPLICATIONS OF STEM-CELL THERAPY (INCLUDING AUTOLOGOUS STEM CELLS USED WITH ALLOGRAFTS AND BONE SUBSTITUTES) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2194064-DECCC9A84D	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	GENETIC TESTING - NEXT GENERATION SEQUENCING FOR ASSESSMENT OF MEASURABLE RESIDUAL DISEASE (E.G., CLONOSEQ) IN HEMATOLOGICAL MALIGNANCIES - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2198889	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	CIRCULATING TUMOR DNA FOR MANAGEMENT OF NON-SMALL CELL LUNG CANCER (LIQUID BIOPSY) (EFFECTIVE 09/01/2026)PayerPolicy · BCBSM-2210513-81150D6F78	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	IN-OFFICE NEEDLE ARTHROSCOPY (E.G., MI-EYE 2, MI-EYE 3 NEEDLESCOPE WITH CANNULA, AND VISIONSCOPE) - MEDICARE ADVANTAGEPayerPolicy · BCBSM-2196216-E7B2A306B1	New policy
Aug 2, 2026	Blue Cross Blue Shield of Michigan and Blue Care Network	PLATELET RICH PLASMA AUTOLOGOUS PLATELET-DERIVED GROWTH FACTORS AS A TREATMENT OF WOUND HEALING AND OTHER NON-ORTHOPEDIC CONDITIONSPayerPolicy · BCBSM-2199374	New policy